院前碾碎普拉格雷片对拟行直接PCI的STEMI患者的影响:COMPARE CRUSH随机试验
COMPARE CRUSH试验在荷兰多中心纳入727例拟行直接PCI的STEMI患者,随机在救护车中给予碾碎或完整普拉格雷60mg负荷剂量。结果显示碾碎组与完整组在首次造影TIMI 3血流(31.0% vs 32.7%)和PCI后1小时完全ST段回落(59.9% vs 57.3%)上无显著差异,但碾碎组血小板反应性显著更低,出血与缺血事件无差异。
要点
- 院前碾碎普拉格雷未改善直接PCI前TIMI 3血流或PCI后1小时ST段完全回落。
- 碾碎普拉格雷显著降低PCI开始时的血小板反应性(P2Y12反应单位192 vs 227)。
- 两组TIMI大出血和BARC≥3出血及30天缺血事件均无显著差异。
核心结论
- 对拟行直接PCI的STEMI患者,院前给予碾碎普拉格雷片不改善直接PCI前梗死相关动脉TIMI 3血流或PCI后1小时完全ST段回落。
研究设计与样本
- 随机对照、多中心试验,在荷兰纳入727例拟行直接PCI的STEMI患者。
- 患者随机在救护车转运前接受普拉格雷60mg负荷剂量,碾碎片或完整片。
主要发现
- 直接PCI前梗死相关动脉TIMI 3血流:碾碎组31.0% vs 完整组32.7%(OR 0.92,95%CI 0.65-1.30,P=0.64)。
- PCI后1小时完全(≥70%)ST段回落:碾碎组59.9% vs 完整组57.3%(OR 1.11,95%CI 0.78-1.58,P=0.55)。
- PCI开始时P2Y12反应单位:碾碎组192(132-245) vs 完整组227(184-254),P≤0.01。
- TIMI大出血:碾碎组0% vs 完整组0.8%;BARC≥3出血:碾碎组0.3% vs 完整组1.1%。
- 30天缺血事件两组无差异。
关键数值与推荐
- 主要终点为直接PCI前梗死相关动脉TIMI 3血流和PCI后1小时完全(≥70%)ST段回落。
- 安全终点为TIMI大出血和BARC≥3出血。
- 研究治疗至PCI导丝通过的中位时间为57(47-70)分钟。
临床怎么用
- 不推荐仅为了改善直接PCI前再灌注而常规院前碾碎普拉格雷给药。
- 碾碎普拉格雷可更快抑制血小板反应性,但未转化为临床再灌注获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early treatment with a potent oral platelet P2Y12 inhibitor is recommended in patients presenting with ST-segment-elevation myocardial infarction scheduled to undergo primary percutaneous coronary intervention (pPCI). The impact on coronary reperfusion of crushed P2Y12 inhibitor tablets, which lead to more prompt and potent platelet inhibition, is unknown. METHODS: We conducted a randomized controlled, multicenter trial in the Netherlands, enrolling patients with ST-segment-elevation myocardial infarction scheduled to undergo pPCI. Patients were randomly allocated to receive in the ambulance, before transfer, a 60-mg loading dose of prasugrel either as crushed or integral tablets. The independent primary end points were thrombolysis in myocardial infarction (TIMI) 3 flow in the infarct-related artery at initial coronary angiography, and complete (≥70%) ST-segment resolution 1 hour after pPCI. The safety end points were TIMI major and Bleeding Academic Research Consortium ≥3 bleedings. Secondary end points included platelet reactivity and ischemic outcomes. RESULTS: A total of 727 patients were assigned to either crushed or integral tablets of prasugrel loading dose. The median time from study treatment to wire-crossing during pPCI was 57 (47-70) minutes. The primary end point TIMI 3 flow in the infarct-related artery before pPCI occurred in 31.0% in the crushed group versus 32.7% in the integral group (odds ratio, 0.92 [95% CI, 0.65-1.30], P=0.64). Complete ST-segment resolution 1 hour after pPCI was present in 59.9% in the crushed group versus 57.3% in the integral group (odds ratio, 1.11 [95% CI, 0.78-1.58], P=0.55). Platelet reactivity at the beginning of pPCI, measured as P2Y12 reactivity unit, differed significantly between groups (crushed, 192 [132-245] versus integral, 227 [184-254], P≤0.01). TIMI major and Bleeding Academic Research Consortium ≥3 bleeding occurred in 0% in the crushed group versus 0.8% in the integral group, and in 0.3% in the crushed group versus 1.1% in the integral group, respectively. There were no differences observed between groups regarding ischemic events at 30 days. CONCLUSIONS: Prehospital administration of crushed prasugrel tablets does not improve TIMI 3 flow in the infarct-related artery before pPCI or complete ST-segment resolution 1 h after pPCI in patients presenting with ST-segment-elevation myocardial infarction scheduled for pPCI. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03296540.
引用
- Vlachojannis GJ, Wilschut JM, Vogel RF, et al. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. Circulation. 2020. PMID: 33315489. doi:10.1161/CIRCULATIONAHA.120.051532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。